Company intelligence / Profile preview

Cypre

San Francisco, California, United States

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Cypre has developed a proprietary 3D organoid technology that recreates human tumor microenvironments, allowing pharmaceutical and biotech partners to screen drugs for efficacy, mechanism of action, and drug resistance in vitro. The platform is being used for beta testing by academics and custom contracts with pharma, but no clinical trial results yet[1][2][3][6][7].

Therapeutic areas: Oncology
Modalities: DeviceHydrogel-based drug delivery therapy3D organoid platform
Industry: Non-Drug Biotech

Partnerships

Charles River Laboratories (strategic partnership for 3D in vitro cancer immunotherapy and targeted therapy drug screening)[7]Cedars-Sinai Hospital (academic collaboration)[2]

Beyond the preview

Go deeper on Cypre.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cypre.

Explore the full profile